Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
The purpose of this study is to see what effects, good and/or bad, proton radiation, and/or conventional radiation and hormonal therapy (if applicable), has on prostate cancer that has already returned or the risk of prostate cancer returning.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * Prostate cancer treated primarily with open, laparoscopic or robotically assisted prostatectomy. * Maximum PSA value of 20 ng/ml. Exclusion Criteria: * Evidence of distant metastasis (M1). * Prior systemic chemotherapy for any reason. * Previous irradiation to the pelvis that would compromise the ability to deliver the prescribed study treatment. * Active inflammatory bowel disease (Crohn's disease, diverticulitis or ulcerative colitis) affecting the rectum. (Non-active diverticulitis and Crohn's disease not affecting the rectum are allowed). * Prior or concurrent cancer, other than non-melanomatous skin cancer, unless disease free for at least 5 years. * Taking Saw Palmetto or methotrexate and unable or unwilling to discontinue its use during radiation.
Study sites (6)
AR
- Proton Center of Arkansas · Little Rock, AR 72205Monica Coleman · Study contact · 501-686-8274 · mmcoleman@uams.eduSanjay Maraboyina, MD · Principal investigatorMore trials in Little Rock
FL
- University of Florida Proton Therapy Institute · Jacksonville, FL 32206Intake Coordinator · Study contact · 877-686-6009Samuel Jean-Baptiste, MD · Principal investigatorMore trials in Jacksonville
IL
- Northwestern Medicine Chicago Proton Center · Warrenville, IL 60555Don Smith, MS, CCRC · Study contact · 630-933-7820 · donald.smith3@nm.orgArpi Thukral, MD · Principal investigatorMore trials in Warrenville
MI
- McLaren Proton Therapy Center · Flint, MI 48532Stacy Freeman · Study contact · 313-576-8495 · freemans@karmanos.orgBrian Yeh, MD · Principal investigatorMore trials in Flint
MO
- Mercy David C. Pratt Cancer Center · St Louis, MO 63141Nancy Umbeck · Study contact · 314-251-7066 · nancy.umbeck@mercy.netAmit Roy, MD · Principal investigatorMore trials in St Louis
VA
- Inova Schar Cancer Institute · Fairfax, VA 22031Sangeetha Moturi · Study contact · 571-472-0343 · sangeetha.moturi@inova.orgKevin Choe, MD · Principal investigatorMore trials in Fairfax